TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33568344
Drug: Atezolizumab (anti-PD-L1),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (anti-PD-L1), administered intravenously every 3 weeks until confirmed disease progression or loss of clinical benefit.
Study: 33568345
Drug: Crizotinib at
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib at the recommended phase II dose of 280 mg/m²
Study: 33568350
Drug: Additional immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional immune modulators (tumor necrosis factor-alpha inhibitor 77%, mycophenolate 23%) in addition to systemic steroids
Study: 33568350
Drug: Additional immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional immune modulators
Study: 33568360
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (10.8% at baseline, 46.5% moderate-intensity, 4.6% high-intensity)
Study: 33568360
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (4.2% at baseline, increased to 41.6% at 3 months, decreased to 20.8% at 1 year, increased to 38.9% at 2 years)
Study: 33568367
Drug: L-POCUS (lung
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-POCUS (lung point-of-care ultrasonography) performed within 48 hours following ED admission
Study: 33568367
Drug: L-POCUS score
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-POCUS score assessment
Study: 33568367
Drug: Second L-POCUS
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second L-POCUS performed at day 5±3
Study: 33568367
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment as recommended by WHO
Study: 33569214
Drug: Etoposide capsules
Normalized name: Etoposide Capsules
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide capsules (25 mg/50 mg) as maintenance therapy, once a day for 20 days, every 28 days until disease progression.
Study: 33569214
Drug: Observation (non-maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (non-maintenance therapy, NMT) group.
Study: 33569214
Drug: Etoposide capsules
Normalized name: Etoposide Capsules
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide capsules (25 mg) in stage I.
Study: 33569311
Drug: RRx-001 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RRx-001 treatment in combination with a platinum doublet
Study: 33569311
Drug: RRx-001 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RRx-001 treatment
Study: 33569494
Drug: BI 1265162
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1265162 single doses ≤1200 µg
Study: 33569494
Drug: BI 1265162
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1265162 multiple doses of 600 µg
Study: 33570247
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PARP inhibitor (PARPi) and EZH2 inhibitor
Study: 33571166
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pioglitazone and mirabegron
Study: 33571520
Drug: Neogenin expression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neogenin expression in DIPG tumors, specific dosage and duration not available
Study: 33573594
Drug: Peer-led exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-led exercise program, twice a week for 12 weeks, led by a trained leader of the same age.
Study: 33574446
Drug: Intensity-modulated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensity-modulated radiation therapy (IMRT) with a dose of 50 Gy (25 fractions of 2 Gy over 5 weeks)
Study: 33574913
Drug: Sitagliptin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin combined with metformin (Sig)
Study: 33574913
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (Ins)
Study: 33734135
Drug: Entecavir therapy
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir therapy
Study: 33576388
Drug: Criteria for
Normalized name: DIMETHICONE 1 g in 100 mL TOPICAL GEL [JAFRA Fruteria So Citrico]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Criteria for treatment futility
Study: 33577756
Drug: Micropulse trans-scleral
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micropulse trans-scleral laser therapy (mTLT)
Study: 33578615
Drug: Navigated transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navigated transcranial magnetic stimulation (TMS) priming with transcranial direct current stimulation (tDCS) combined with constraint-induced movement therapy (CIMT)
Study: 33579332
Drug: Attachment-Based Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attachment-Based Family Therapy (ABFT) for 16 weeks, consisting of weekly therapy sessions (family/individual or both) according to the treatment manual.
Study: 33579332
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) for 16 weeks, not monitored.
Study: 33579739
Drug: Atezolizumab and
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab and nab-paclitaxel (specific dosage and duration not mentioned)
Study: 33579774
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen therapy (HFOT)
Study: 33580779
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of miRNA panel and hs-cTnT reference
Study: 33581080
Drug: Tezacaftor-ivacaftor (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezacaftor-ivacaftor (oral tezacaftor 100 mg once daily and oral ivacaftor 150 mg once every 12 hours for up to 96 weeks)
Study: 33581379
Drug: Accelerated rTMS
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated rTMS course (arTMS) of 6 sessions/day over 5 days (30 total) followed by tapering course of daily sessions (up to 25)
Study: 33582392
Drug: Selective internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective internal radiation therapy
Study: 33582418
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of mirogabalin
Study: 33582418
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of pregabalin
Study: 33585031
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) 8 mg/kg intravenously or 162 mg subcutaneously
Study: 33585031
Drug: Corticosteroids (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (CS) methylprednisolone 80 mg/day
Study: 33585503
Drug: Low Soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Soluble Receptor for Advanced Glycation End Products
Study: 33585999
Drug: Ruxolitinib (10-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (10-25 mg bid) in combination with weekly paclitaxel (80 mg/m)
Study: 33586174
Drug: Narrowband ultraviolet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrowband ultraviolet B (NB-UVB) treatment for 36 sessions
Study: 33586174
Drug: Narrowband ultraviolet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrowband ultraviolet B (NB-UVB) treatment
Study: 33586581
Drug: Bendamustine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 200 mg/m²
Study: 33586590
Drug: RO6870810 (BET
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO6870810 (BET inhibitor)
Study: 33587156
Drug: Cold atmospheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold atmospheric plasma (CAP) treatment for 2 min on Staphylococcus aureus in collagen-elastin matrices
Study: 33587156
Drug: Cold atmospheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold atmospheric plasma (CAP) treatment for 2 min on Staphylococcus aureus on dermal samples
Study: 33587156
Drug: Cold atmospheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold atmospheric plasma (CAP) treatment for 2 min on human dermal samples
Study: 33587156
Drug: Repeated daily
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated daily CAP treatments for 2 min on dermal samples
Study: 33587156
Drug: Repeated CAP
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated CAP treatment for 2 min on ex vivo human burn wound models
Study: 33587156
Drug: Cold atmospheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold atmospheric plasma (CAP) treatment for 3× 20" on intact skin of volunteers
Study: 33587156
Drug: Cold atmospheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold atmospheric plasma (CAP) treatment on intact skin of 15 volunteers contaminated with Pseudomonas aeruginosa
Study: 33587156
Drug: Lowering the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowering the plasma power during CAP treatment
Study: 33587435
Drug: Sofosbuvir-based DAA
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir-based DAA therapy + Ribavirin (RBV)
Study: 36686592
Drug: Sofosbuvir-based DAA
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir-based DAA therapy
Study: 33588149
Drug: ABTL0812 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABTL0812 at 1300 mg three times a day (RP2D)
Study: 33588149
Drug: ABTL0812 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABTL0812 at 500 mg once a day to 2000 mg twice a day (escalation phase)
Study: 33588922
Drug: Daratumumab 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab 16 mg/kg intravenously once weekly for Cycles 1 and 2, every other week for Cycles 3 through 6, and every 4 weeks thereafter until progression or unacceptable toxicity; all cycles were 28 days.
Study: 33588922
Drug: Daratumumab 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab 16 mg/kg intravenously
Study: 33588925
Drug: cDPP3 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: cDPP3 levels > 40.4 ng/mL upon admission
Study: 33589404
Drug: Higher insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher insulin concentration
Study: 33589538
Drug: Intensive arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive arm motor therapy
Study: 33589714
Drug: Multi-domain program
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-domain program (24-week, bi-weekly) including dual-task exercises, cognitive training, and mobile application-based nutritional guidance
Study: 33590273
Drug: bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: bolus injection of LAT-1 targeting PET tracer
Study: 33591016
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of cerebral tissue oxygen saturation desaturation
Study: 33591143
Drug: 0.5% isobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% isobaric bupivacaine with 20 μg of fentanyl
Study: 33591291
Drug: Nonpharmacological interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonpharmacological interventions administered by a comfort coach
Study: 33591402
Drug: Standardized treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized treatment for pediatric renal tumors (e.g., bilateral Wilms tumor)
Study: 33591402
Drug: Targeted and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted and immune therapies
Study: 33591468
Drug: Enzalutamide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide (160 mg oral daily) plus trastuzumab (6 mg/kg intravenous every 21 days)
Study: 33593135
Drug: Sublingual tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual tacrolimus 0.04 mg/kg/dose twice daily
Study: 33593135
Drug: Oral tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tacrolimus (after sublingual administration)
Study: 33593311
Drug: FOLFIRINOX (5-fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX (5-fluorouracil, irinotecan and oxaliplatin) and hypofractionated SBRT (5 fractions, total dose of 30 Gy with simultaneous integrated boost of 50 Gy on tumor-vessel interface) followed by IORT (10 Gy)
Study: 33593430
Drug: RBX2660 (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBX2660 (one or two doses)
Study: 33593448
Drug: Intravitreal sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal sirolimus monotherapy (every 2 months)
Study: 33593448
Drug: Anti-vascular endothelial
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-vascular endothelial growth factor (VEGF) (monthly)
Study: 33593448
Drug: Intravitreal sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal sirolimus monotherapy
Study: 33593763
Drug: Clinical characteristics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical characteristics, including demographics, pathology, treatment and prognosis of patients with GBC in China
Study: 33593867
Drug: IV immunoglobulin
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV immunoglobulin (IVIG) treatment
Study: 33593994
Drug: Non-vitamin K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-vitamin K antagonist oral anticoagulants (NOAC)
Study: 33594075
Drug: Neoadjuvant anti-OX40
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neoadjuvant anti-OX40 (MEDI6469) therapy
Study: 33594602
Drug: CRLX301 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRLX301 at 75 mg/m2 Q3W
Study: 33596161
Drug: High-risk obstructive
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk obstructive sleep apnea treatment
Study: 33596309
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma GLP-1 concentrations in the obesity clinic group (median 3.3 pmol/L; interquartile range, 2.3-4.3 pmol/L)
Study: 33597152
Drug: Oral glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucocorticoid therapy, immunotherapies, and biologic therapy
Study: 33598475
Drug: Saffron extract
Normalized name: saffron extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron extract (30 mg standardized saffron extract for 8 weeks)
Study: 33598844
Drug: Roux-en-Y gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roux-en-Y gastric bypass (group A: one oral hypoglycemic agent)
Study: 33598942
Drug: Bendamustine (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine (30, 40, or 60 mg/m²) in combination with clofarabine, etoposide, and dexamethasone for 5 days
Study: 33598942
Drug: Bendamustine (substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine (substituted for cyclophosphamide) in combination with clofarabine and etoposide
Study: 33599941
Drug: High-protein plant-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein plant-based diet (~ 1.6 g kg)
Study: 33600102
Drug: Intestinal mucosal
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intestinal mucosal samples for IgE antibody determination
Study: 33601057
Drug: AAV8-RS1 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AAV8-RS1 gene therapy
Study: 33602286
Drug: Intraarticular injection
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injection of umbilical cord-derived Wharton's Jelly (UC-derived WJ)
Study: 33602316
Drug: Belinostat (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belinostat (1000 mg/m2) combined with CHOP (Bel-CHOP)
Study: 33602316
Drug: Belinostat (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belinostat (1000 mg/m2) on Day 1-3 schedule
Study: 33602316
Drug: Belinostat (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belinostat (1000 mg/m2) on Day 1-5 schedule
Study: 33602696
Drug: Hexatherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexatherapy regimen composed of adenovirus-based vaccine, IL-15 superagonist (N-803), anti-OX40, anti-4-1BB, anti-PD-L1, and docetaxel.
Study: 33602926
Drug: Standard TB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard TB therapy
Study: 33602926
Drug: Experimental TB
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental TB treatment (did not reduce Mtb bacterial load)
Study: 33604400
Drug: Convalescent COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent COVID-19 plasma (CCP) treatment
Study: 33604458
Drug: Concurrent paclitaxel-based
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concurrent paclitaxel-based chemoradiotherapy (CRT)
Study: 33604947
Drug: Morphine equivalent
Normalized name: paregoric 2 MG (as morphine equivalent) in 5 mL Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine equivalent dose
Study: 33605445
Drug: Obinutuzumab (GA101;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obinutuzumab (GA101; G) alone (G-mono)
Study: 33605445
Drug: Obinutuzumab (G)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab (G) with fludarabine and cyclophosphamide (G-FC)
Study: 33605445
Drug: Obinutuzumab (G)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab (G) with bendamustine (G-bendamustine)
Study: 33605465
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (AHT) including β-blockers and/or ACE inhibitors
Study: 33605465
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with VIT treatment failure
Study: 34826124
Drug: CZP 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 400 mg Q2W
Study: 33606269
Drug: CZP 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 400 mg Q2W and CZP 200 mg Q2W
Study: 33606269
Drug: CZP 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 400 mg Q2W, CZP 200 mg Q2W, and placebo
Study: 33606312
Drug: Nasal allergen
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal allergen challenge (NAC) with cockroach extract (0.00381-11.9 µg/mL Bla g 1)
Study: 33606418
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume ventilation (LTVV), defined as VT of 8 ml kg-1 or less predicted bodyweight (PBW)
Study: 33606655
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management app delivered via care packages
Study: 33607477
Drug: NBTXR3 (intratumoural
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBTXR3 (intratumoural injection) followed by intensity-modulated radiation therapy (IMRT; 70 Gy)
Study: 33619368
Drug: Anti-BCMA CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-BCMA CAR T cell therapy
Study: 33608053
Drug: Lymphodepleting chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepleting chemotherapy (LDC)
Study: 33608060
Drug: Buprenorphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine treatment with measurement based care (MBC)
Study: 33608263
Drug: Renin-Angiotensin-Aldosterone System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Treatment
Study: 33608377
Drug: ABBV-428 administered
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-428 administered intravenously every 2 weeks at doses between 0.01 and 3.6 mg/kg.
Study: 33609856
Drug: 200 ug
Normalized name: DROXIDOPA 200 ug ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ug adjunctive estradiol treatment
Study: 33610169
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with Habit Reversal Training (HRT) and Exposure Response Prevention (ERP)
Study: 33610169
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with HRT and ERP (individual or group setting)
Study: 33610169
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with HRT and ERP
Study: 33610319
Drug: Weekly IV
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly IV paclitaxel with carboplatin and bevacizumab (regimen 2)
Study: 33610453
Drug: Osimertinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib plus single-agent chemotherapy (n=29)
Study: 33610453
Drug: Osimertinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib plus chemotherapy
Study: 33610500
Drug: Haploidentical K562-mb15-41BBL-activated
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haploidentical K562-mb15-41BBL-activated and expanded NK (NKAE) cells; 13 infusions administered after a lymphodepleting regimen
Study: 33612455
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg, every 3 weeks)